Neurocrine has bellied up to the deal table, snagging commercial rights to 4 gene therapy development programs at Voyager Therapeutics — including their lead mid-stage treatment for Parkinson-s disease — for $165 million in cash split between an upfront payment and a $50 million equity stake, plus another $1.5 billion in milestone money.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription